Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Clinical trial NCT00267202 · COMPLETED

Trial details

NCT number: NCT00267202
Sponsor: Novartis
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Allergic Asthma

Start date: 2005-12-01
Primary completion: 2008-01-01
Enrollment: 275

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.